There is limited research on the association between 25-hydroxyvitamin D levels and meniscus injury. This study investigated serum 25-hydroxyvitamin D (25-OHD) in meniscus injury patients and its association with other bioinorganic chemistry of micronutrients, and immune cells numbers from January 2023 to December 2023. A total of 198 participants were recruited between the age of 18 and 89 years. Participants with renal or liver failure, or any other chronic conditions, who were taking medications that might affect the metabolism of vitamin D, were not included in the study. In this study, we categorized serum 25(OH)D concentrations as follows: ≤30ngm/dl was categorized as insufficient, and >30ngm/dl was deemed sufficient. Among the 198 participants, 82% (n=162) were serum 25(OH)D deficient, while only 18% (n=36) participants were serum 25(OH)D sufficient. No significant difference observed in vitamin D deficiency among difference age, BMI, sex, blood pressure, inflammatory cell numbers, and other vitamins compared to the vitamin D sufficient group. Moreover, the serum 25(OH)D concentrations were negatively related to the severity of meniscus injury based on MRI examination. In conclusion, severe vitamin D deficiency is more common in patients with meniscus injury and may play a significant role in their prognosis.

The authors have declared no competing interest.

This study did not receive any funding

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

All data produced in the present study are available upon reasonable request to the authors